New drugs, diagnostic approved for advanced melanoma

(HealthDay)—Two new drugs, Tafinlar (dabrafenib) and Mekinist (trametinib), have been approved by the U.S. Food and Drug Administration to treat advanced melanoma, the most dangerous form of skin cancer.

Melanoma, the leading cause of death from skin disease, is expected to be diagnosed in more than 76,000 people this year, and about 9,480 are expected to die from it, the FDA said Wednesday in a news release. Tafinlar is approved for people with an abnormality in the BRAF V600E gene, while Mekinist is approved for people with a mutation in either the BRAF V600E or V600K genes, the agency said.

A newly approved companion diagnostic, the THxID BRAF test, will help determine if a person has a mutation in either gene, the FDA said.

The most serious side effects reported in people getting Tafinlar included increased risk of a less severe form of skin cancer (cutaneous ), fever, , shaking chills, dehydration, and a rise in blood sugar, the agency said.

The most serious side effects of Mekinist included heart failure, , skin infection and loss of vision.

Both drugs also could cause infertility or harm a developing fetus, the FDA said.

Tafinlar and Mekinist are marketed by North Carolina-based GlaxoSmithKline. The THxID BRAF test is manufactured by bioMerieux, based in France.

More information: To learn more about these approvals, visit the FDA.

add to favorites email to friend print save as pdf

Related Stories

Simponi approved for ulcerative colitis

May 15, 2013

(HealthDay)—Simponi (golimumab) injection has been approved by the U.S. Food and Drug Administration to treat adults with moderate-to-severe ulcerative colitis.

FDA approves genetic test for lung cancer drug

May 14, 2013

The Food and Drug Administration says it approved a genetic test from Roche to help doctors identify patients who can benefit from a lung cancer drug made by Genentech.

Recommended for you

User comments